{
    "clinical_study": {
        "@rank": "15108", 
        "arm_group": {
            "arm_group_label": "Revlite Laser System", 
            "arm_group_type": "Experimental", 
            "description": "Revlite Laser System"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of the Revlite Laser System for\n      treatment of facial solar lentigines"
        }, 
        "brief_title": "Study for the RevLite Laser System for Facial Solar Lentigines", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Facial Solar Lentigines", 
        "condition_browse": {
            "mesh_term": [
                "Facies", 
                "Lentigo"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is a healthy male or female between 18 and 60 years old.\n\n          2. Is Fitzpatrick Skin types I-III\n\n          3. Is willing to consent to participate in the study.\n\n          4. Is willing to comply with all requirements of the study including being photographed,\n             following post treatment care and attending all treatment and follow up visits.\n\n          5. Has clinically determined mild to severe facial mottled pigmentation (solar\n             lentigines) on the face.\n\n        Exclusion Criteria:\n\n          1. Is female and pregnant, has been pregnant within the last 3 months, is currently\n             breast feeding or planning a pregnancy during the study period.\n\n          2. Is hypersensitive to light exposure OR takes photo sensitized medication.\n\n          3. Has active or localized systemic infections.\n\n          4. Has a coagulation disorder or is currently using anti-coagulation medication\n             (including but not limited to the heavy use of aspirin {greater than 81 mg per day}).\n\n          5. Has any condition which, in the investigator's opinion, would make it unsafe for the\n             subject to participate in this research study.\n\n          6. Is currently enrolled in an investigational drug or device trial, or has received an\n             investigational drug or been treated with an investigational device within 3 months\n             prior to entering this study.\n\n          7. Has used Accutane within 6 months prior to enrollment.\n\n          8. Has the need to be exposed to artificial tanning devices or excessive sunlight during\n             the trial.\n\n          9. Has had prior treatment with parenteral gold therapy (gold sodium thiomalate).\n\n         10. Has a history of keloids.\n\n         11. Has evidence of compromised wound healing.\n\n         12. Has a history of basal cell carcinoma, squamous cell carcinoma or melanoma.\n\n         13. Has a history of immunosuppression/immune deficiency disorders (including HIV\n             infection or AIDS) or use of immunosuppressive medications or has an autoimmune\n             disorder."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110108", 
            "org_study_id": "CYN14-REV-REJUV-NS"
        }, 
        "intervention": {
            "arm_group_label": "Revlite Laser System", 
            "description": "Revlite Laser System for the Treatment of Facial Solar Lentigines", 
            "intervention_name": "Revlite Laser System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10075"
                }, 
                "name": "Sadick Research Group"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study for the RevLite Laser System for Facial Solar Lentigines", 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Photos taken at baseline will be compared to photos taken 1 month post last treatment to assess level of improvement using the Global Aesthetic Improvement Scale", 
            "measure": "Photographic evaluation using the Global Aesthetic Improvement Scale", 
            "safety_issue": "No", 
            "time_frame": "1 month post last treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110108"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Satisfaction Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "1 month post last treatment"
        }, 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}